Shopping Cart
- Remove All
- Your shopping cart is currently empty
CLM3, a pyrazolopyrimidine derivative, functions as a multitargeted tyrosine kinase inhibitor. It exhibits antiproliferative and proapoptotic activities on endothelial and cancer cells, activities that are synergistically enhanced by SN38. The primary mechanism of action for CLM3 involves the inhibition of phosphorylation in tyrosine kinases such as VEGFR-2, EGFR, and RET, along with their associated signaling pathways.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | CLM3, a pyrazolopyrimidine derivative, functions as a multitargeted tyrosine kinase inhibitor. It exhibits antiproliferative and proapoptotic activities on endothelial and cancer cells, activities that are synergistically enhanced by SN38. The primary mechanism of action for CLM3 involves the inhibition of phosphorylation in tyrosine kinases such as VEGFR-2, EGFR, and RET, along with their associated signaling pathways. |
In vitro | CLM3 (0-100 μM, 72 h) significantly reduces the levels of phosphorylated VEGFR-2, phosphorylated EGFR, and phosphorylated RET in activated endothelial and cancer cells. Additionally, CLM3 (0-100 μM, 72 h) markedly inhibits the expression of the cyclin D1 gene and decreases the intracellular concentration of cyclin D1 protein in both endothelial and cancer cells. |
Molecular Weight | 343.43 |
Formula | C21H21N5 |
Cas No. | 1312024-59-1 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.